MRE-269 (ACT-333679)

MRE-269, also known as ACT-333679, is a long-acting and highly selective prostacyclin receptor agonist. MRE-269, the active form or metabolite of Selexipag (NS-304), is much more selective for the IP receptor than are the prostacyclin analogs beraprost and iloprost, which also have high affinity for the EP(3) receptor.

Synonyms:

4-(3,5-dichlorophenylureido)phenoxyisobutyric acid;

2-[4-({[(3,5-DICHLOROPHENYL)AMINO]CARBONYL}AMINO)PHENOXY]-2-METHYLPROPANOIC ACID;

2-<4<<<(3,5-dichlorophenyl)amino>carbonyl>amino>phenoxy>-2-methylpropionic acid;

2-(4-{[(3,5-dichlorophenyl)carbamoyl]amino}phenoxy)-2-methylpropanoic acid;

{4-[(5,6-diphenylpyrazin-2-yl)(isopropyl)amino]butoxy}acetic acid;

2-{4-[N'-(3,5-dichlorophenyl)ureido]phenoxy}isobutyric acid;

Selexipag intermediate;

Prostaglandin Receptor Related Products:

E-7046; Ramatroban; Ozagrel; Bimatoprost; Prostaglandin E2; Tafluprost; Carboprost; Treprostinil sodium; Travoprost; Misoprostol; Selexipag; Setipiprant

[1]. Fuchikami C, et al. A comparison of vasodilation mode among selexipag (NS-304; [2-{4-[(5,6-diphenylpyrazin-2-yl)(isopropyl)amino]butoxy}-N-(methylsulfonyl)acetamide]), its active metabolite MRE-269 and various prostacyclin receptor agonists in rat, porcin

[2]. Orie NN, et al. Differential actions of the prostacyclin analogues treprostinil and iloprost and the selexipag metabolite, MRE-269 (ACT-333679) in rat small pulmonary arteries and veins. Prostaglandins Other Lipid Mediat. 2013 Oct;106:1-7